HC Wainwright Has Lowered Expectations for Inventiva (NASDAQ:IVA) Stock Price

Inventiva (NASDAQ:IVA) had its price target dropped by stock analysts at HC Wainwright to $14.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price target would suggest a potential upside of 268.42% from the stock’s previous close.

IVA has been the topic of several other research reports. Guggenheim raised their price target on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Cantor Fitzgerald initiated coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating on the stock. Weiss Ratings upgraded shares of Inventiva from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. Truist Financial boosted their price target on shares of Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Finally, Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Inventiva has a consensus rating of “Moderate Buy” and a consensus target price of $14.67.

Inventiva Stock Up 4.7%

NASDAQ:IVA traded up $0.17 during trading hours on Thursday, hitting $3.80. The stock had a trading volume of 2,220,541 shares, compared to its average volume of 2,884,170. The company has a 50 day simple moving average of $3.73 and a two-hundred day simple moving average of $4.83. Inventiva has a one year low of $2.82 and a one year high of $7.29.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The firm had revenue of $0.75 million for the quarter. Analysts anticipate that Inventiva will post -0.79 EPS for the current fiscal year.

Institutional Trading of Inventiva

Several hedge funds and other institutional investors have recently bought and sold shares of IVA. Seven Fleet Capital Management LP bought a new position in Inventiva during the first quarter valued at approximately $1,111,000. Commonwealth Equity Services LLC boosted its stake in shares of Inventiva by 7.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company’s stock valued at $332,000 after purchasing an additional 5,857 shares in the last quarter. Engineers Gate Manager LP boosted its stake in shares of Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after purchasing an additional 43,280 shares in the last quarter. Platt Investment Counsel LLC purchased a new stake in shares of Inventiva in the 3rd quarter valued at $45,000. Finally, Aberdeen Group plc grew its holdings in shares of Inventiva by 36.3% during the 3rd quarter. Aberdeen Group plc now owns 3,145,711 shares of the company’s stock valued at $11,608,000 after purchasing an additional 837,938 shares during the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.